湖南启元律师事务所 关于湖南达嘉维康医药产业股份有限公司 2025年第四次临时股东会的 法律意见书 二零二五年十二月一日 致：湖南达嘉维康医药产业股份有限公司 湖南启元律师事务所（以下简称"本所"）接受湖南达嘉维康医药产业股份 有限公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第四次 临时股东会（以下简称"本次股东会"），对本次股东会的召集和召开程序、出 席会议人员及召集人的资格、表决程序和表决结果的合法有效性进行律师见证， 并发表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《湖 南达嘉维康医药产业股份有限公司章程》（以下简称"《公司章程》"）的有关 规定出具本法律意见书。 为出具本法律意见书，本所律师声明如下： （一）本所律师出具本法律意见书是基于公司已承诺所有提供给本所律师的 文件的正本以及经本所律师查验与正本保持一致的副本均为真实、完整、可靠， 无隐瞒、虚假或重大遗漏之处。 （二）本所律师遵循了勤勉尽责和诚 ...

Core Viewpoint - The company has launched its oseltamivir phosphate granules for the treatment of influenza amid a widespread outbreak of H1N1, ensuring a stable supply of medications to meet seasonal demand [2]. Group 1: Product Availability - The company's subsidiary, Hunan Tianji Caotang Pharmaceutical Co., Ltd., has begun selling oseltamivir phosphate granules in major offline pharmacies across the country [2]. - The medication is suitable for patients aged 2 weeks and older for the treatment of both type A and type B influenza, and for prevention in patients aged 1 year and older [2]. Group 2: Market Response - The company has a range of over-the-counter medications available in its retail pharmacies, including fever reducers and cough suppressants, to address symptomatic treatment for influenza [2]. - In response to the seasonal increase in demand, the company has developed a production plan that allows for flexible adjustments in capacity based on market sales conditions, ensuring a safe and stable supply of medications [2].

Core Points - Dajia Weikang announced the early termination of a share reduction plan by a major shareholder, Mr. Zhong Xuesong [1] - Mr. Zhong reduced his holdings by 2,050,700 shares, representing 1.00% of the company's total share capital [1] - Following the reduction, Mr. Zhong's shareholding decreased from 19,288,356 shares to 17,237,656 shares, lowering his ownership percentage from 9.39% to 8.39% [1] Summary by Categories - **Shareholder Actions** - Mr. Zhong Xuesong, a shareholder with over 5% stake, informed the company about the early termination of his share reduction plan [1] - The reduction occurred between September 1, 2025, and November 20, 2025, through centralized bidding [1] - **Shareholding Changes** - The total shares reduced were 2,050,700, which is 1.00% of the total share capital [1] - Post-reduction, Mr. Zhong's total shares held decreased to 17,237,656, resulting in a new ownership percentage of 8.39% [1]

Core Points - Dajia Weikang (301126) announced the early termination of a share reduction plan by major shareholder and director Zhong Xuesong [1] - Zhong Xuesong reduced his holdings by 2.0507 million shares, representing 1% of the company's total share capital, from September 1 to November 20 [1] - Following the reduction, Zhong's shareholding decreased from 9.39% to 8.39%, totaling 17.2377 million shares [1] Summary by Sections - **Shareholder Activity** - Zhong Xuesong, a shareholder with over 5% stake, has communicated the early termination of his share reduction plan [1] - The reduction of 2.0507 million shares occurred through centralized bidding transactions [1] - **Shareholding Changes** - After the reduction, Zhong Xuesong's total shareholding is now 17.2377 million shares [1] - The percentage of total share capital held by Zhong decreased from 9.39% to 8.39% [1] - **Future Plans** - Zhong Xuesong will not proceed with any further reductions of shares during the remaining period of the reduction plan [1]

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

Core Viewpoint - The company announced that a major shareholder, Mr. Zhong Xuesong, has decided to terminate his share reduction plan ahead of schedule, having already reduced his holdings by 2,050,700 shares, which is 1.00% of the total share capital [1] Summary by Relevant Sections - **Shareholder Activity** - Mr. Zhong Xuesong reduced his shareholding from 19,288,356 shares to 17,237,656 shares, decreasing his ownership percentage from 9.39% to 8.39% [1] - The reduction occurred between September 1, 2025, and November 20, 2025, through centralized bidding transactions [1] - **Reduction Plan Status** - The share reduction plan has been terminated early, and no further shares will be sold during the remaining period of the plan [1]

格隆汇11月20日丨达嘉维康(301126.SZ)公布，公司近日收到持股5%以上股东、董事钟雪松先生出具的 《关于提前终止股份减持计划的告知函》，获悉钟雪松先生于2025年9月1日至2025年11月20日期间，通 过集中竞价交易方式累计减持公司股份2,050,700股，占公司总股本的1.00%，其持股数量由19,288,356 股减少至17,237,656股，持有公司股份占公司总股本比例由9.39%降低至8.39%。钟雪松先生决定提前终 止本次股份减持计划，未完成减持的股份在剩余减持计划期间内将不再减持。 ...

达嘉维康公告，持股5%以上股东兼董事钟雪松原拟2025年9月1日至11月30日减持不超350万股（占 1.70%）。截至2025年11月20日已通过集中竞价减持205.07万股，减持均价12.53元/股，占1.00%，持股 数由1928.84万股降至1723.77万股，持股比例由9.39%降至8.39%。钟雪松决定提前终止本次减持计划， 剩余期间不再减持。 ...

湖南达嘉维康医药产业股份有限公司 关于持股 5%以上股东、董事提前终止股份减持计划的公告 公司持股 5%以上股东、董事钟雪松保证向本公司提供的信息真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：301126 证券简称：达嘉维康 公告编号：2025-076 1 二、其他相关说明 1、5%以上股东、董事钟雪松先生本次减持符合《中华人民共和国公司法》《中 华人民共和国证券法》《深圳证券交易所创业板股票上市规则》《上市公司股东减 持股份管理暂行办法（2025 年修订）》《上市公司董事和高级管理人员所持本公司 股份及其变动管理规则》《深圳证券交易所上市公司自律监管指引第 18 号——股东 及董事、高级管理人员减持股份（2025 年修订）》等法律法规、部门规章及规范性 文件的规定。 2、5%以上股东、董事钟雪松先生的本次减持计划已按照相关规定进行了预披 露。截至本公告披露日，钟雪松先生减持股份情况与此前已经披露的减持计划一致， 不存在违反已披露的减持计划及相关承诺的情形。截至本公告披露日，本次减持计 划提前终止，未完成减持的股份在剩余减持计划期间内将不再减持。 3、截至本公告披露日，钟雪松先生严格遵守 ...

Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.42% on November 19, with Ailong Technology leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the medical consumables supply chain SPD sector showed mixed performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while several others, including Guoyao Yici and Jiuzhoutong, saw declines of 0.55% and 0.59% respectively [1] - The trading volume and turnover for Jianfa Zhixin were 180,800 hands and 620 million yuan, respectively [1] Capital Flow - The medical consumables supply chain SPD sector saw a net outflow of 99.05 million yuan from main funds, while retail investors contributed a net inflow of 74.72 million yuan [2] - Notable individual stock capital flows included Jianfa Zhixin with a net inflow of 70.39 million yuan from main funds, while Ailong Technology experienced a net outflow of 2.99 million yuan [3]